Comparison of the actions of γ-butyrolactone and 1,4-butanediol in Swiss-Webster mice

Pharmacology Biochemistry and Behavior

Volumn 77, Issue 4, 2004, Pages 705-710

  De Fiebre, Christopher M ^a   De Fiebre, Nancy Ellen C ^a   Coleman, Scott L ^a   Forster, Michael J ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Butyrolactone; Hydroxybutyrate; 1,4 Butanediol; Club drugs; Hypothermia; Locomotor activity

Indexed keywords

1,4 BUTANEDIOL; GAMMA BUTYROLACTONE; SODIUM CHLORIDE;

ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; HYPOTHERMIA; LOCOMOTION; MALE; MOUSE STRAIN; NONHUMAN; PRECURSOR; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT;

4-BUTYROLACTONE; ANIMALS; BODY TEMPERATURE; BUTYLENE GLYCOLS; MALE; MICE; MOTOR ACTIVITY;

EID: 1942455422     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2004.01.009     Document Type: Article

References (36)

1. Carai M.A., Colombo G., Reali R., Serra S., Mocci I., Castelli M.P.et al. Central effects of 1,4-butanediol are mediated by GABA(B) receptors via its conversion into gamma-hydroxybutyric acid. Eur. J. Pharmacol. 441:2002;157-163.
2. Catalano M., Glass J., Catalano G., Burrows S., Lynn W., Weitzner B. Gamma butyrolactone (gbl) withdrawal syndromes. Psychosomatics. 42:2001;83-88.
3. Collier B., De Feudis F.V. Conversion of gamma-hydroxybutyrate to gamma-aminobutyrate by mouse brain in vivo. Experientia. 26:1970;1072-1073.
4. Colombo G., Agabio R., Lobina C., Reali R., Fadda F., Gessa G.L. Cross-tolerance to ethanol and gamma-hydroxybutyric acid. Eur. J. Pharmacol. 95(273):1995;235-238.
5. Cook C.D., Aceto M.D., Coop A., Beardsley P.M. Effects of the putative antagonist NCS382 on the behavioral pharmacological actions of gammahydroxybutyrate in mice. Psychopharmacology (Berl.). 160:2002;99-106.
6. Davies J.A. The effect of gamma-butyrolactone on locomotor activity in the rat. Psychopharmacology (Berl.). 78(60):1978;67-72.
7. de Fiebre C.M., Medhurst L.J., Collins A.C. Nicotine response and nicotinic receptors in long-sleep and short-sleep mice. Alcohol. 4:1987;493-501.
8. de Fiebre N.C., Marley R.J., Wehner J.M., Collins A.C. Lipid solubility of sedative-hypnotic drugs influences hypothermic and hypnotic responses of long-sleep and short-sleep mice. J. Pharmacol. Exp. Ther. 263:1992;232-240.
9. de Fiebre N.C., Dawson R. Jr., de Fiebre C.M. The selectively-bred high alcohol sensitivity (HAS) and low alcohol sensitivity (LAS) rats differ in sensitivity to nicotine. Alcohol. Clin. Exp. Res. 26:2002;765-772.
10. Dudek B.C., Fanelli R.J. Effects of gamma-butyrolactone, amphetamine, and haloperidol in mice differing in sensitivity to alcohol. Psychopharmacology (Berl.). 68:1980;89-97.
11. Dyer J.E., Roth B., Hyma B.A. Gamma-hydroxybutyrate withdrawal syndrome. Ann. Emerg. Med. 37:2001;147-153.
12. Gianutsos G., Moore K.E. Tolerance to the effects of baclofen and gamma-butyrolactone on locomotor activity and dopaminergic neurons in the mouse. J. Pharmacol. Exp. Ther. 78(207):1978;859-869.
13. Guidotti A., Ballotti P.L. Relationship between pharmacological effects and blood and brain levels of gamma-butyrolactone and gamma-hydroxybutyrate. Biochem. Pharmacol. 19:1970;883-894.
14. Hechler V., Ratomponirina C., Maitre M. Gamma-hydroxybutyrate conversion into GABA induces displacement of GABAB binding that is blocked by valproate and ethosuximide. J. Pharmacol. Exp. Ther. 281:1997;753-760.
15. Irwin RD. NTP summary report on the metabolism, disposition, and toxicity of 1,4-butanediol (CAS No 110-63-4). Toxic Rep Ser 1996;54:1-28, A1-8, B1-5.
16. Itzhak Y., Ali S.F. Repeated administration of gamma-hydroxybutyric acid (GHB) to mice: assessment of the sedative and rewarding effects of GHB. Ann. N. Y. Acad. Sci. 965:2002;451-460.
17. Kaufman E.E., Porrino L.J., Nelson T. Pyretic action of low doses of gamma-hydroxybutyrate in rats. Biochem. Pharmacol. 40:1990;2637-2640.
18. Lettieri J., Fung H.L. Improved pharmacological activity via pro-drug modification: comparative pharmacokinetics of sodium gamma-hydroxybutyrate and gamma-butyrolactone. Res. Commun. Chem. Pathol. Pharmacol. 22:1978;107-118.
19. Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog. Neurobiol. 51:1997;337-361.
20. Poldrugo F., Snead O.C. III 1,4 Butanediol, gamma-hydroxybutyric acid and ethanol: relationships and interactions. Neuropharmacology. 84(23):1984;109-113.
21. Poldrugo F., Snead O.C. III 1,4-Butanediol and ethanol compete for degradation in rat brain and liver in vitro. Alcohol. 86(3):1986;367-370.
22. Quang L.S., Desai M.C., Kraner J.C., Shannon M.W., Woolf A.D., Maher T.J. Enzyme and receptor antagonists for preventing toxicity from the gamma-hydroxybutyric acid precursor 1,4-butanediol in CD-1 mice. Ann. N. Y. Acad. Sci. 965:2002;461-472.
23. Quang L.S., Shannon M.W., Woolf A.D., Desai M.C., Maher T.J. Pretreatment of CD-1 mice with 4-methylpyrazole blocks toxicity from the gamma-hydroxybutyrate precursor, 1,4-butanediol. Life Sci. 71:2002;771-778.
24. Roth R.H., Giarman N.J. Gamma-butyrolactone and gamma-hydroxybutyric acid: I. Distribution and metabolism. Biochem. Pharmacol. 15:1966;1333-1348.
25. Roth R.H., Delgado J.M., Giarman N.J. Gamma-butyrolactone and gamma-hydroxybutyric acid: II. The pharmacologically active form. Int. J. Neuropharmacol. 5:1966;421-428.
26. SAMHSA Club drugs. The Dawn Report. Office of Applied Studies, Substance Abuse and Mental Health Services Administration (SAMHSA). 2000;1-10. Dec.
27. Schneidereit T., Burkhart K., Donovan J.W. Butanediol toxicity delayed by preingestion of ethanol. Int. J. Med. Toxicol. 3:2000;1.
28. Shannon M., Quang L.S. Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: a case report and review of the literature. Pediatr. Emerg. Care. 16:2000;435-440.
29. Snead O.C. III An investigation of the relationship between the dopaminergic and electroencephalographic effects of gamma-butyrolactone. Neuropharmacology. 21:1982;539-543.
30. Snead O.C. III Gamma-hydroxybutyric acid-induced seizures bear no relation to core temperature. Epilepsia. 31:1990;253-258.
31. Snead O.C. III, Furner R., Liu C.C. In vivo conversion of gamma-aminobutyric acid and 1,4-butanediol to gamma-hydroxybutyric acid in rat brain. Studies using stable isotopes. Biochem. Pharmacol. 89(38):1989;4375-4380.
32. Teter C.J., Guthrie S.K. A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy. 21:2001;1486-1513.
33. Uzbay I.T., Wallis C.J., Lal H., Forster M.J. Effects of NMDA receptor blockers on cocaine-stimulated locomotor activity in mice. Behav. Brain Res. 108:2000;57-61.
34. Vayer P., Mandel P., Maitre M. Conversion of gamma-hydroxybutyrate to gamma-aminobutyrate in vitro. J. Neurochem. 45:1985;810-814.
35. Winger G., Hursh S.R., Casey K.L., Woods J.H. Relative reinforcing strength of three N-methyl-D-aspartate antagonists with different onsets of action. J. Pharmacol. Exp. Ther. 301:2002;690-697.
36. Zvosec D.L., Smith S.W., McCutcheon J.R., Spillane J., Hall B.J., Peacock E.A. Adverse events, including death, associated with the use of 1,4-butanediol. N. Engl. J. Med. 344:2001;87-94.